Shanghai Yizhong announced that the phase I clinical trial of the innovative drug YXC-001 developed by its wholly-owned subsidiary Shanghai Youxichuang Pharmaceutical Technology Co., Ltd. recently completed the first dose in the first dose group, and the safety is good. This test uses a dose escalation design to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics characteristics of the product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.